Company intelligence / Profile preview

ImClone Systems

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

ImClone's lead program Erbitux (cetuximab) is FDA approved for metastatic colorectal cancer and head and neck cancer; their pipeline included follow-on antibodies (e.g., IMC-11F8, later called necitumumab) and other biologics, some of which reached late clinical (Phase II/III) or commercial stages[2][3][6][7].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

Bristol Myers Squibb (co-marketing Erbitux in North America, shared R&D)Merck KGaA (co-development/marketing Erbitux in Japan and Europe)

Beyond the preview

Go deeper on ImClone Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImClone Systems.

Explore the full profile